Brii Bio results


Pay attention to baseline HBsAg…very low in this study…pegIFN alone in these type of patients with very low baseline HBsAg achieves functional cure rates as high as 30%.

In order to understand the true potential of these therapies, phase II trials must be conducted excluding patients with < 1000 IU/mL of HBsAg. The average HBsAg level in patients with chronic HBV infection is ~10,000 IU/mL.

yep. I saw that

16% (5/31) of participants demonstrated sustained HBsAg loss 24 weeks after end of treatment; Two of the five participants had baseline HBsAg levels greater than 1,000 IU/mL. No new safety findings were observed during the follow-up.

I’d like to know what exact numbers are those > 1000 :wink: